NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, ...
Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. The erosion was obvious. After MSN Pharmaceuticals opened the floodgates to Entresto generics in ...
Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of ...
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results